{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:10:13Z","timestamp":1787163013701,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.amjmed.2025.02.024","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:04:58Z","timestamp":1741115098000},"page":"1074-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Lipoprotein(a) in the Progression of Aortic Stenosis"],"prefix":"10.1016","volume":"138","author":[{"given":"Clay","family":"Sherrill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-0221","authenticated-orcid":false,"given":"Lauren","family":"Ehrhardt-Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeb","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.amjmed.2025.02.024_bib0001","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0735-1097(92)90520-W","article-title":"Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease","volume":"19","author":"Genest","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2025.02.024_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.numecd.2021.10.015","article-title":"Lipoprotein(a) and aortic valve stenosis: a casual or causal association?","volume":"32","author":"Santangelo","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.amjmed.2025.02.024_bib0003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.amjmed.2025.02.024_bib0004","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/eurheartj\/ehac377","article-title":"Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification","volume":"43","author":"Kaiser","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.amjmed.2025.02.024_bib0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2025.02.024_bib0006","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: a systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.amjmed.2025.02.024_bib0007","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.amjmed.2025.02.024_bib0008","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: the Copenhagen general population study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"17","key":"10.1016\/j.amjmed.2025.02.024_bib0009","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.amjmed.2025.02.024_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006339","article-title":"Valve interstitial cells: the key to understanding the pathophysiology of heart valve calcification","volume":"6","author":"Rutkovskiy","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2025.02.024_bib0011","unstructured":"Shurmur SW. American College of Cardiology. Lp(a), aortic stenosis, and atherogenicity. Available at: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2019\/11\/25\/08\/57\/Lp-a-Aortic-Stenosis-and-Atherogenicity. Accessed September 25, 2024."},{"issue":"39","key":"10.1016\/j.amjmed.2025.02.024_bib0012","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.amjmed.2025.02.024_bib0013","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","article-title":"Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease","volume":"13","author":"Moriarty","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjmed.2025.02.024_bib0014","unstructured":"Feingold KR. Lipoprotein Apheresis. [Updated 2023 Feb 19]. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK425700\/"},{"key":"10.1016\/j.amjmed.2025.02.024_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.amjmed.2025.02.024_bib0016","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2025.02.024_bib0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10408363.2017.1415866","article-title":"Lipoprotein(a) in clinical practice: new perspectives from basic and translational science","volume":"55","author":"Scipione","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.amjmed.2025.02.024_bib0018","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2025.02.024_bib0019","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"10.1016\/j.amjmed.2025.02.024_bib0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10057","key":"10.1016\/j.amjmed.2025.02.024_bib0021","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.amjmed.2025.02.024_bib0022","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2025.02.024_bib0023","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2025.02.024_bib0024","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.amjmed.2025.02.024_bib0025","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2025.02.024_bib0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.amjmed.2025.02.024_bib0027","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.amjmed.2025.02.024_bib0028","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.amjmed.2025.02.024_bib0029","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432500138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432500138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:05:01Z","timestamp":1749791101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293432500138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S000293432500138X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.02.024","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Lipoprotein(a) in the Progression of Aortic Stenosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}